https://www.technologydigestyemen.com/article/905424235-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.technologydigestyemen.com/article/905424236-communiqu-de-presse-dupixent-de-sanofi-et-regeneron-approuv-dans-l-ue-comme-premier-m-dicament-cibl-contre-l-urticaire-chronique-spontan-e-chez Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.technologydigestyemen.com/article/905424237-wisesat-et-le-commandement-de-l-espace-des-forces-arm-es-suisses-finalisent-la-phase-pilote-et-pr-parent-la-mission-de-nouvelle-g-n-ration-wisesat-6u Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 WISeSat et le Commandement de l’Espace des Forces armées suisses finalisent la phase pilote et préparent la mission de nouvelle génération WISeSat 6U prévue pour novembre 2026 https://ml-eu.globenewswire.com/media/80dae807-c8a0-4e1a-a0f0-61afcc7ae788/small/ https://www.technologydigestyemen.com/article/905424241-wisesat-and-swiss-space-command-of-the-swiss-armed-forces-complete-pilot-phase-and-prepare-next-generation-wisesat-6u-mission-planned-for-november Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 WISeSat and Swiss Space Command of the Swiss Armed Forces Complete Pilot Phase and Prepare Next-Generation WISeSat 6U Mission Planned for November 2026 https://ml-eu.globenewswire.com/media/80dae807-c8a0-4e1a-a0f0-61afcc7ae788/small/wisekey-logo-png.png https://www.technologydigestyemen.com/article/905424242-wisesat-et-le-commandement-de-l-espace-des-forces-arm-es-suisses-finalisent-la-phase-pilote-et-pr-parent-la-mission-de-nouvelle-g-n-ration-wisesat-6u Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 WISeSat et le Commandement de l’Espace des Forces armées suisses finalisent la phase pilote et préparent la mission de nouvelle génération WISeSat 6U prévue pour novembre 2026 https://ml-eu.globenewswire.com/media/80dae807-c8a0-4e1a-a0f0-61afcc7ae788/small/ https://www.technologydigestyemen.com/article/905424246-data-published-in-nature-communications-highlights-unique-mechanism-of-action-of-alpibectir-in-combination-with-ethionamide-alpe Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://www.technologydigestyemen.com/article/905424249-dupixent-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu Technology Digest Yemen en PressRelease 2026-04-13T05:00:00+00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.technologydigestyemen.com/article/905400865-bitcoin-poker-no-deposit-bonus-2026-bc-poker-offers-10-free-to-play-online-poker-for-real-money-with-no-cashout-cap-provably-fair-tables-and Technology Digest Yemen en PressRelease 2026-04-13T02:00:00+00:00 Bitcoin Poker No Deposit Bonus 2026: BC Poker Offers $10 Free to Play Online Poker for Real Money With No Cashout Cap, Provably Fair Tables, and Instant Crypto Withdrawals https://ml.globenewswire.com/media/328735a6-4b55-4daa-990f-5abb0fe5e067/medium/bc-poker.png https://www.technologydigestyemen.com/article/905385512-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia Technology Digest Yemen en PressRelease 2026-04-12T23:30:00+00:00 Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.technologydigestyemen.com/article/905245340-crypto-news-alphapepe-stage-12-nears-sell-out-while-xrp-price-prediction-targets-10-following-new-clarity-act-victory Technology Digest Yemen en PressRelease 2026-04-12T02:00:00+00:00 Crypto News: AlphaPepe Stage 12 Nears Sell Out While XRP Price Prediction Targets $10 Following New Clarity Act Victory https://ml.globenewswire.com/media/a8e79e81-dded-4e4a-8ce6-cbc3aebc7c1c/medium/alphapepe.jpg https://www.technologydigestyemen.com/article/905241699-unix-ai-claims-first-real-home-deployment-of-mass-produced-humanoid-robot-panther Technology Digest Yemen en PressRelease 2026-04-12T01:23:51+00:00 UniX AI Claims First Real-Home Deployment of Mass-Produced Humanoid Robot Panther https://ml.globenewswire.com/media/8605e61c-ae74-4335-bf0b-659cf666be5d/small/unix-logo-jpg.jpg https://www.technologydigestyemen.com/article/905190593-gelatine-sculpt-unveiled-does-this-pink-gelatin-trick-for-weight-loss-legit-read-gelatine-sculpt-report Technology Digest Yemen en PressRelease 2026-04-11T19:09:47+00:00 Gelatine Sculpt Unveiled: Does This Pink Gelatin Trick for Weight Loss Legit? Read Gelatine Sculpt Report! https://ml.globenewswire.com/media/46f10c1b-b2b7-48f4-9b09-e6377d6b4096/medium/gelatine-sculpt.png https://www.technologydigestyemen.com/article/905116581-biontech-and-dualitybio-s-antibody-drug-conjugate-trastuzumab-pamirtecan-demonstrated-clinically-meaningful-efficacy-in-patients-with-her2-expressing Technology Digest Yemen en PressRelease 2026-04-11T11:00:00+00:00 BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.technologydigestyemen.com/article/905116769-biontechs-und-dualitybios-antik-rper-wirkstoff-konjugat-kandidat-trastuzumab-pamirtecan-zeigte-klinisch-relevante-wirksamkeit-bei-patientinnen-mit Technology Digest Yemen en PressRelease 2026-04-11T11:00:00+00:00 BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.technologydigestyemen.com/article/905104435-city-furniture-and-garvee-explore-omnichannel-retail-collaboration-in-north-america Technology Digest Yemen en PressRelease 2026-04-11T10:00:00+00:00 City Furniture and GARVEE Explore Omnichannel Retail Collaboration in North America https://ml.globenewswire.com/media/470f187e-99c7-4c56-9e8d-fd187adb34a0/small/ga-logo-jpg.jpg https://www.technologydigestyemen.com/article/905104471-cookiy-introduces-a-user-research-suite-that-enables-any-ai-to-talk-to-real-people Technology Digest Yemen en PressRelease 2026-04-11T09:42:03+00:00 Cookiy Introduces a User Research Suite That Enables Any AI to Talk to Real People https://ml.globenewswire.com/media/fda45332-8b9e-40d8-b02b-1d6012b526e1/medium/cookiy-ai.jpg